pentobarbital will decrease the level or effect of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Carefully. Advisable atogepant dosage with concomitant utilization of sturdy or average CYP3A4 inducers is 30 mg or sixty mg qDay.
pentobarbital will decrease the level or result of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lower the level or result of dienogest/estradiol valerate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Females should not select estradiol valerate/dienogest as their contraceptive whilst making use of sturdy CYP3A4 inducers as a consequence of opportunity minimize in contraceptive efficacy.
pentobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral method of both brokers. Slight/Importance Unidentified.
pentobarbital will boost the stage or result of ivosidenib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration of ivosidenib with potent CYP3A4 inducers lowered ivosidenib plasma concentrations.
pentobarbital will reduce the level or result of mifepristone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. CYP3A4 inducers have not been examined, coadministration not proposed by maker
With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital more info will lower the level or effect of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; powerful cytochrome P450 enzyme inducers reduce systemic publicity to roflumilast and could decrease the therapeutic success
Contraindicated (one)pentobarbital will reduce the extent or effect of dienogest/estradiol valerate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Females mustn't opt for estradiol valerate/dienogest as their contraceptive though employing robust CYP3A4 inducers as a consequence of opportunity decrease in contraceptive efficacy.
Constantly keep an eye on vital signs through sedation and Restoration period if coadministered. Meticulously titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
pentobarbital will minimize the extent or outcome of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital boosts effects of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Watch. Coadministration of ifosfamide with CYP2B6 inducers might boost metabolism of ifosfamide to its metabolite. Watch for increased effects/toxicities if combined with CYP2B6 inducers.
Monitor Closely (1)pentobarbital will lower the level or influence of benzhydrocodone/acetaminophen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Caution when discontinuing CYP3A4 inducers which are coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone could enhance and may lead to most likely lethal respiratory despair.
pentobarbital will decrease the extent or effect of methadone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.